Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial

INTRODUCTION: Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection of immunocompromised hosts with significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15–20 mg/kg/day, is associated with serious adverse drug events (...

Descripción completa

Detalles Bibliográficos
Autores principales: Sohani, Zahra N., Butler-Laporte, Guillaume, Aw, Andrew, Belga, Sara, Benedetti, Andrea, Carignan, Alex, Cheng, Matthew P., Coburn, Bryan, Costiniuk, Cecilia T, Ezer, Nicole, Gregson, Dan, Johnson, Andrew, Khwaja, Kosar, Lawandi, Alexander, Leung, Victor, Lother, Sylvain, MacFadden, Derek, McGuinty, Michaeline, Parkes, Leighanne, Qureshi, Salman, Roy, Valerie, Rush, Barret, Schwartz, Ilan, So, Miranda, Somayaji, Ranjani, Tan, Darrell, Trinh, Emilie, Lee, Todd C., McDonald, Emily G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310160/
https://www.ncbi.nlm.nih.gov/pubmed/35863836
http://dx.doi.org/10.1136/bmjopen-2021-053039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310160/
https://www.ncbi.nlm.nih.gov/pubmed/35863836
http://dx.doi.org/10.1136/bmjopen-2021-053039

Ejemplares similares